Avicanna Inc. (TSX:AVCN) has recently announced a comprehensive medical cannabis real-world evidence study in collaboration with the MyMedi.ca medical cannabis care platform. The study, overseen by Hance Clarke, MD, FRCPC, Ph.D., President of The Canadian Pain Society and the Canadian Consortium for the Investigation of Cannabinoids, aims to enroll 1,000 patients across Canada for a thorough exploration of the therapeutic potential of medical cannabis and its impact on pain, sleep, anxiety, depression, and epilepsy.
The study, a prospective, non-interventional, observational initiative, seeks to utilize validated questionnaires to analyze the effects of various medical cannabis products and assess changes in the use of concomitant medications over a 24-week period. The primary objective is to enhance understanding of the benefits of medical cannabis for patients seeking therapeutic relief.
Notably, this study represents Avicanna’s commitment to advancing patient care and medical research, particularly in the realm of cannabinoid medicines. The MyMedi.ca medical cannabis care platform, established with the goal of providing access to medical cannabis, patient support, education, and research facilitation, will play a pivotal role in the study’s execution.
Participants in the study will have access to a variety of products offered through the MyMedi.ca platform, including Avicanna’s RHO Phyto formulary, as well as products from licensed producers supporting the research. Avicanna Inc., a global biopharmaceutical company focused on the development and commercialization of cannabinoid-based products, remains at the forefront of innovation in the medical and pharmaceutical sectors.
Shares of Avicanna Inc. (TSX:AVCN) are currently trading at C$0.395, reflecting a decrease of 2.47% as of 12:13 pm ET. This study underscores Avicanna’s dedication to advancing medical cannabis research and its potential benefits for patients, underscoring the company’s commitment to patient-centered care and evidence-based medicine.
